Nuvation Bio (NUVB) Accumulated Depreciation (2020 - 2025)
Nuvation Bio (NUVB) posted quarterly Accumulated Depreciation of $1.2 million for Q4 2025, up 35.47% year-over-year from $874000.0 in Q4 2024, and up 35.47% quarter-over-quarter from $874000.0 in Q4 2024.
Nuvation Bio (NUVB) Accumulated Depreciation (2020 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Accumulated Depreciation for 6 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 35.47% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 35.47% YoY), while the FY2025 annual figure was $1.2 million, up 35.47% from the prior year.
- Accumulated Depreciation rose to $1.2 million in Q4 2025 per NUVB's latest filing, from $874000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $1.2 million in Q4 2025 and bottomed at $291000.0 in Q4 2021.
- Historically, Accumulated Depreciation has averaged $694600.0 across 5 years, with a median of $666000.0 in 2023.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation soared 150.86% — and 2024, when it surged 31.23%.
- Nuvation Bio's Accumulated Depreciation stood at $291000.0 in 2021, then soared by 57.39% to $458000.0 in 2022, then surged by 45.41% to $666000.0 in 2023, then soared by 31.23% to $874000.0 in 2024, then jumped by 35.47% to $1.2 million in 2025.
- Business Quant data shows NUVB's Accumulated Depreciation at $1.2 million in Q4 2025, $874000.0 in Q4 2024, and $666000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 874,000.00 |
| Dec 31, 2023 | 666,000.00 |
| Dec 31, 2022 | 458,000.00 |
| Dec 31, 2021 | 291,000.00 |
| Dec 31, 2020 | 116,000.00 |